SEK 0.43
(-1.61%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | -193 Thousand SEK | 0.0% |
2022 | -193 Thousand SEK | -0.52% |
2021 | -192 Thousand SEK | 0.52% |
2020 | -193 Thousand SEK | 0.0% |
2019 | -193 Thousand SEK | 0.0% |
2018 | -193 Thousand SEK | 59.54% |
2017 | -477 Thousand SEK | -532.94% |
2016 | -75.36 Thousand SEK | 84.92% |
2015 | -499.69 Thousand SEK | -31.44% |
2014 | -380.16 Thousand SEK | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q1 | -48 Thousand SEK | 0.0% |
2024 Q2 | - SEK | 100.0% |
2024 Q3 | - SEK | 0.0% |
2023 Q3 | -48 Thousand SEK | 0.0% |
2023 Q2 | -48 Thousand SEK | 0.0% |
2023 FY | -193 Thousand SEK | 0.0% |
2023 Q1 | - SEK | 100.0% |
2023 Q4 | -48 Thousand SEK | 0.0% |
2022 Q2 | -48 Thousand SEK | 0.0% |
2022 Q1 | -48 Thousand SEK | 2.04% |
2022 Q4 | -48 Thousand SEK | 0.0% |
2022 Q3 | -48 Thousand SEK | 0.0% |
2022 FY | -193 Thousand SEK | -0.52% |
2021 Q1 | -48 Thousand SEK | 0.0% |
2021 Q2 | -48 Thousand SEK | 0.0% |
2021 Q4 | -49 Thousand SEK | -2.08% |
2021 FY | -192 Thousand SEK | 0.52% |
2021 Q3 | -48 Thousand SEK | 0.0% |
2020 Q3 | - SEK | 0.0% |
2020 Q4 | - SEK | 0.0% |
2020 Q1 | - SEK | 0.0% |
2020 FY | -193 Thousand SEK | 0.0% |
2020 Q2 | - SEK | 0.0% |
2019 Q3 | - SEK | 0.0% |
2019 FY | -193 Thousand SEK | 0.0% |
2019 Q4 | - SEK | 0.0% |
2019 Q2 | - SEK | 0.0% |
2019 Q1 | - SEK | 0.0% |
2018 Q2 | - SEK | 0.0% |
2018 Q1 | - SEK | 0.0% |
2018 Q3 | - SEK | 0.0% |
2018 Q4 | - SEK | 0.0% |
2018 FY | -193 Thousand SEK | 59.54% |
2017 Q1 | - SEK | 0.0% |
2017 FY | -477 Thousand SEK | -532.94% |
2017 Q2 | - SEK | 0.0% |
2017 Q3 | - SEK | 0.0% |
2017 Q4 | - SEK | 0.0% |
2016 Q2 | - SEK | 0.0% |
2016 Q1 | - SEK | 0.0% |
2016 FY | -75.36 Thousand SEK | 84.92% |
2016 Q4 | - SEK | 0.0% |
2016 Q3 | - SEK | 0.0% |
2015 FY | -499.69 Thousand SEK | -31.44% |
2014 FY | -380.16 Thousand SEK | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
Alligator Bioscience AB (publ) | -160.68 Million SEK | 99.88% |
Ziccum AB (publ) | -23.28 Million SEK | 99.171% |
Modus Therapeutics Holding AB (publ) | - SEK | Infinity% |
BioArctic AB (publ) | 346.31 Million SEK | 100.056% |
Sprint Bioscience AB (publ) | 41.78 Million SEK | 100.462% |
Mendus AB (publ) | 28.48 Million SEK | 100.678% |
Genovis AB (publ.) | 54 Million SEK | 100.357% |
Intervacc AB (publ) | -13.79 Million SEK | 98.601% |
QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | 108.89% |
Active Biotech AB (publ) | -1.67 Million SEK | 88.478% |
Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | 101.937% |
Bio-Works Technologies AB (publ) | 26.82 Million SEK | 100.72% |
Aptahem AB (publ) | 2.63 Million SEK | 107.337% |
Vicore Pharma Holding AB (publ) | -3.42 Million SEK | 94.358% |
Kancera AB (publ) | -1.96 Million SEK | 90.178% |
Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | 350.649% |
Fluicell AB (publ) | 1.73 Million SEK | 111.105% |
Saniona AB (publ) | 11.78 Million SEK | 101.638% |
Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | 96.228% |
Biovica International AB (publ) | 6.87 Million SEK | 102.806% |
Spago Nanomedical AB (publ) | -23.28 Million SEK | 99.171% |
AcouSort AB (publ) | 8.38 Million SEK | 102.301% |
Xintela AB (publ) | 78 Thousand SEK | 347.436% |
Abliva AB (publ) | -35.66 Million SEK | 99.459% |
Egetis Therapeutics AB (publ) | -146.9 Million SEK | 99.869% |
Karolinska Development AB (publ) | 2.8 Million SEK | 106.876% |
OncoZenge AB (publ) | 3000.00 SEK | 6533.333% |
Amniotics AB (publ) | -1.93 Million SEK | 90.0% |
2cureX AB (publ) | -37.48 Million SEK | 99.485% |
CombiGene AB (publ) | -21.29 Million SEK | 99.094% |
Asarina Pharma AB (publ) | -423 Thousand SEK | 54.374% |
Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 100.017% |
Camurus AB (publ) | 1.58 Billion SEK | 100.012% |
Corline Biomedical AB | 28.38 Million SEK | 100.68% |
IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 99.843% |
Isofol Medical AB (publ) | -34.41 Million SEK | 99.439% |
I-Tech AB | 27.56 Million SEK | 100.7% |
Hansa Biopharma AB (publ) | 70.95 Million SEK | 100.272% |
Cyxone AB (publ) | 2.61 Million SEK | 107.392% |
ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | 105.671% |
Biosergen AB | -456 Thousand SEK | 57.675% |
Cantargia AB (publ) | -3.45 Million SEK | 94.407% |
NextCell Pharma AB | -43.74 Million SEK | 99.559% |
Xspray Pharma AB (publ) | -9.19 Million SEK | 97.901% |
Elicera Therapeutics AB (publ) | 11.21 Million SEK | 101.72% |
Nanologica AB (publ) | -76 Thousand SEK | -153.947% |
SynAct Pharma AB | -778 Thousand SEK | 75.193% |
Stayble Therapeutics AB (publ) | - SEK | Infinity% |
LIDDS AB (publ) | -12.92 Million SEK | 98.506% |
Lipum AB (publ) | 53 Thousand SEK | 464.151% |
BioInvent International AB (publ) | 71.46 Million SEK | 100.27% |
Alzinova AB (publ) | 19.87 Million SEK | 100.971% |
Oncopeptides AB (publ) | 36.29 Million SEK | 100.532% |
Pila Pharma AB (publ) | 1.46 Million SEK | 113.192% |
Guard Therapeutics International AB (publ) | -15 Thousand SEK | -1186.667% |
Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | 111.641% |
Simris Alg AB (publ) | 2 Million SEK | 109.616% |
Diamyd Medical AB (publ) | -3.58 Million SEK | 94.609% |
Xbrane Biopharma AB (publ) | 35.38 Million SEK | 100.545% |
Ascelia Pharma AB (publ) | -1.04 Million SEK | 81.602% |
Diagonal Bio AB (publ) | 3.13 Million SEK | 106.16% |